Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Gains from Investment Securities (2016 - 2025)

Traws Pharma (TRAW) has disclosed Gains from Investment Securities for 13 consecutive years, with $3000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $3000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.2 million, a N/A change, with the full-year FY2024 number at $423107.0, up 357.7% from a year prior.
  • Gains from Investment Securities was $3000.0 for Q3 2025 at Traws Pharma, up from -$146000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $24.4 million in Q4 2024 to a low of -$26.5 million in Q1 2025.
  • A 4-year average of -$318500.0 and a median of -$77500.0 in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 909.52% in 2021; the steepest drop was 862.5% in 2021.
  • Traws Pharma's Gains from Investment Securities stood at -$530000.0 in 2021, then soared by 98.3% to -$9000.0 in 2022, then skyrocketed by 271633.33% to $24.4 million in 2024, then tumbled by 99.99% to $3000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Gains from Investment Securities are $3000.0 (Q3 2025), -$146000.0 (Q2 2025), and -$26.5 million (Q1 2025).